

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

X



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)
[Back](#)

[Memorial Sloan Kettering Treatment](#)
[Tangible Materials Available for Licensing](#)
[Learn About Cancer & Treatment](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA

of Caov-3 ovarian carcinoma cells *in vitro*. These cells express the NB/70K, CA-125, Ba-2, and Ca-1 tumor-associated antigens. The Caov-3 cells harbor a nonsense mutation in the *p53* gene, and have multiple copies of the ovarian cancer oncogene *PIK3CA*. They are sensitive to vinblastine, cisplatin, and adriamycin. These cells fail to grow in soft agar but are tumorigenic when injected into immunocompromised mice.

Source

This cell line was established from the primary tumor of a 54-year-old Caucasian female with adenocarcinoma of the ovary.

Inventors

Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

- Buick RN et al. (1985) Comparative properties of five human ovarian adenocarcinoma cell lines. *Cancer Research* 45: 3668-3676 (PubMed ID: [4016745](#))
- Yaginuma Y et al. (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. *Cancer Research* 52: 4196-4199 (PubMed ID: [1638534](#))
- Shayesteh L et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. *Nature Genetics* 21: 99 - 102 (PubMed ID: [9916799](#))

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

- Express License: For internal research purposes by a for-profit entity: 1) Fill out MSK's ATCC Express License, see [here](#) for links to the online fillable ATCC Express License, as well as a PDF version. 2) After execution by MSK, you will receive a signed copy, and can then place your order with ATCC. For detailed guidance on how to fill out this webform, see [here](#) . Please note: In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to \$10,000 must be made by credit card.
- Commercial License: Contact MSK's Tangible Materials team at TRMOTDRTM@mskcc.org .

For non-licensing requests from academic-research institutions : Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, [646-888-2354](#) , weisgarf@mskcc.org .

Stage of Development

Ready to use

Indications

[Cancer](#) → [Ovarian](#)

Types

[Research Tools](#) → [Cell Lines](#)

© 2026 Memorial Sloan Kettering Cancer Center